Announcements
- Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
- Purple Biotech Reaches Recommended Phase 2 Dose for NT219
- Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
- Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
- Purple Biotech Fortifies NT219 Patent Protection
More ▼
Key statistics
On Friday, Purple Biotech Ltd (1YI1:DUS) closed at 0.55, 49.46% above the 52 week low of 0.368 set on Apr 17, 2024.
52-week range
Open | 0.545 |
---|---|
High | 0.555 |
Low | 0.540 |
Bid | 0.540 |
Offer | 0.590 |
Previous close | 0.540 |
Average volume | 1.72k |
---|---|
Shares outstanding | 27.53m |
Free float | 24.76m |
P/E (TTM) | -- |
Market cap | 16.11m USD |
EPS (TTM) | -0.7402 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:30 BST.
More ▼